Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway

Details for Australian Patent Application No. 2012204032 (hide)

Owner Dana-Farber Cancer Institute Emory University The Brigham and Women's Hospital, Inc. President and Fellows of Harvard College

Inventors Freemon, Gordon; Sharpe, Arlene; Dorfman, David M.; Ahmed, Rafi; Barber, Daniel; Wherry, E. John

Agent Fisher Adams Kelly

Pub. Number AU-A-2012204032

Parent 2006254902

Filing date 9 July 2012

Wipo publication date 26 July 2012

International Classifications

C07K 16/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 Medicinal preparations containing antigens or antibodies - Antibodies

G01N 33/53 Investigating or analysing materials by specific methods not covered by groups - Immunoassay

Event Publications

26 July 2012 Application Open to Public Inspection

  Published as AU-A-2012204032

26 July 2012 Complete Application Filed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012204033-Attachment for rotary material processing machines

2012204031-Oral care product and methods of use and manufacture thereof